GenoMed Launches National Marketing Campaign
CONTACT: GenoMed Inc.
David W. Moskowitz, MD, MA, FACP
(314) 652-0500
dwmoskowitz@genomedics.com
FOR IMMEDIATE RELEASE
ST. LOUIS, MO. – June 7, 2004 – GenoMed, Inc. (Pink Sheets: GMED), a Next Generation DM™ (Disease Management) company that uses its expertise in genomics to improve clinical outcomes, announced today the launch of its national marketing campaign to improve patient outcomes for diabetes, high blood pressure and emphysema.
GenoMed will host a booth at the 19th Annual National Conference of the American Academy of Nurse Practitioners beginning this Friday in New Orleans (www.aanp.org). GenoMed's patent-pending protocols enable primary care providers to practice effective preventive medicine while bringing in extra revenue. Nurse practitioners are an especially cost-effective delivery mechanism for GenoMed's proprietary treatments.
In St. Louis, GenoMed has begun a radio and print marketing campaign to introduce the public to what the Company can do for patients with high blood pressure, diabetes, and emphysema. Ads have begun appearing on KFUO 99.1 FM, and will soon appear on KLOU 103.3 FM and KMOX 1320 AM. KMOX is the #1 talk radio station in the US, covering 44 states. This week, ads will also appear in the St. Louis Post-Dispatch and the Red Latina, a Spanish paper. The prevalence of diabetes is especially high among Hispanic-Americans.
In August, Dr. David Moskowitz, GenoMed's Chairman and Chief Medical Officer, will give a talk on "Genomic and Biotechnology Applications to Disease Management" in Boston at the Second Annual Disease Management Conference sponsored by the Strategic Research Institute (www.srinstitute.com/dmc). GenoMed will be the only biotechnology company presenting to an audience of health care plans and conventional Disease Management companies looking for ways to improve patient outcomes while cutting healthcare costs. GenoMed's Next Generation DMTM (Disease Management) pioneers the use of genomic and clinical research to improve patient outcomes, and serves as a model for all Disease Management companies to follow.
About GenoMed
GenoMed is leading the clinical revolution which medical genomics has already made possible. GenoMed is currently marketing its protocol for delaying complications like kidney failure due to high blood pressure and diabetes, which affects eighty million Americans. GenoMed is also marketing its method for delaying emphysema, which 3 million Americans have, and another 60 million smokers are at increased risk of getting. In addition, GenoMed is conducting a free nation-wide clinical trial against West Nile virus encephalitis this summer, which will generate revenues in subsequent years.
. |
